Axya Medical raises $6.8m for arthroscopic development
This article was originally published in Clinica
Beverly, Massachusetts-based Axya Medical has raised $6.8m from several venture capital firms led by The Vertical Group, of Summit, New Jersey. Axya president and CEO Paul Fenton said that the funds would be used to support expansion of sales and marketing, secure more distributors in the US and develop new products for the Axya Shoulder Fixation System used in arthroscopic shoulder procedures following sports or other injuries.
You may also be interested in...
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.
Metabesity is a complex issue that will require a multi-disciplinary approach, concerted effort and clear regulatory pathway to achieve solutions.